SSI Strategy Announces Investment from Amulet Capital Partners

Funding will fuel expansion across adjacent Life Sciences functions and help create a business accelerator for emerging cell and gene therapy and rare disease companies.

PARSIPPANY, NJ and GREENWICH, CT, December 21, 2020 – SSI Strategy Holdings LLC (“SSI Strategy” or the “Company”), a leading Life Sciences consultancy, announced today that it has received a growth investment from Amulet Capital Partners, LP (“Amulet”), a middle-market private equity firm focused exclusively on the Healthcare sector. Amulet’s investment, the first institutional funding taken by the Company, will accelerate the growth of SSI Strategy’s team and the expansion of strategic services to support Medical, Clinical and other critical path functions at the C-level of Life Sciences companies.

SSI Strategy is an industry-leading provider of strategic consulting services for scientific functions within Life Sciences companies. The SSI Strategy team supports critical initiatives for Life Sciences companies, ranging in size from emerging biotechs to global leaders.

Adam Schwartz, President of SSI Strategy said, “The partnership with Amulet will fuel SSI Strategy’s growth into adjacent business functions and reinforce our position as an industry-leading consulting firm focused on the full lifecycle of Life Sciences organizations.”

Douglas Locke, CEO of SSI Strategy, stated, “We will also establish a Gene Therapy Accelerator to enable the rapid expansion of early-stage companies through the combination of direct investment and our industry-leading consulting capabilities. SSI Strategy has been a trusted partner to many of the leading cell & gene therapy companies, among other innovative modalities, and our strategic and scientific advice has been pivotal in achieving successful outcomes in some very high-profile programs. The Gene Therapy Accelerator is a logical extension of SSI Strategy’s successful track record in this area. Our aim is to demonstrate our deep commitment to client success, align on mutual long-term interests, and help the pursuit of groundbreaking scientific advances.”

Locke added, “We are thrilled to partner with Amulet on the next steps of our journey. Amulet’s deep experience and focus on the Life Sciences sector is highly aligned with our client needs and SSI Strategy’s strategic vision.”

Nick Amigone, Partner of Amulet stated, “Through our multiple investments in Life Sciences Services, we have experienced firsthand the exciting opportunity around emerging biotechs. These innovative companies are driving the majority of scientific breakthroughs in the Life Sciences sector, but are often in need of strategic guidance, change management capabilities and business process improvements to help them scale. SSI Strategy’s differentiated, high-science service offering is perfectly tailored to the needs of this attractive customer segment.”

Amulet Vice President Avi Uttamchandani added, “As with our past investments in Life Sciences Services companies, we anticipate that our investment in SSI Strategy will be a catalyst for growth. We look forward to partnering with management to fortify what is already a strong foundation, expand into adjacent lines of business and complete accretive tuck-in acquisitions. We are extremely impressed with the business that the SSI Strategy team has built and look forward to supporting them as they bring additional resources to bear on behalf of their clients.”

In conjunction with Amulet’s investment, Simon Kennedy will join SSI Strategy’s Board of Directors. Currently the CEO and Founder of TriAxia Health, Mr. Kennedy has held various leadership positions across the Life Sciences sector, including serving as Executive Chairman of Evidera. Mr. Kennedy was previously a senior partner and managing director at the Boston Consulting Group where he was the founder and global leader of the firm’s health care information technology (HCIT) practice, a member of the committee responsible for BCG’s Value Based Healthcare investments and research and responsible for leading projects across the entire healthcare value chain.

Inverness Advisors acted as exclusive financial advisor to SSI Strategy, and Golenbock, Eiseman, Assor, Bell & Peskoe LLP provided legal counsel. Amulet received legal counsel from Latham & Watkins LLP. Avante Capital Partners provided debt financing for the transaction.

Inverness Advisors conducts all securities business through KEMA Partners LLC, a FINRA member and SEC-registered broker-dealer.

About SSI Strategy

SSI Strategy combines business acumen, medical, clinical and pharmacovigilance domain expertise, and operating experience to provide unparalleled support to our clients. Our staff of ex-Chief Medical Officers and former Heads of Medical Affairs, Clinical Development and Safety will work to ensure the right balance of medical and business focus to drive unparalleled outcomes for clients.

SSI Strategy is headquartered in Parsippany, NJ, with offices in Boston, London, New York, and San Francisco. SSI Strategy has been incubated by Acquis Consulting Group LLC, a premier management consultancy and delivery partner of the firm. For more information on SSI Strategy, please visit www.ssistrategy.com.

About Amulet Capital Partners, LP

Amulet Capital Partners, LP is a middle-market private equity investment firm, focused exclusively on the Healthcare sector. Amulet seeks to achieve long-term capital appreciation through privately negotiated investments in companies. Amulet Capital Partners focuses on those segments it believes have the most attractive long-term fundamentals with a target investment size generally between $25 million to $150 million. Amulet Capital Partners’ investment team has over 80 years of private equity experience. For additional information, please visit www.amuletcapital.com.

Contacts:

For SSI Strategy:
Dan Arabia
973-479-0489

For Amulet Capital Partners:
Melissa Sheer
Kent Place Communications
917-690-2199